Stay updated with breaking news from Lymphoma Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate, and a median duration of response of 1.5 years (18.4 months) - - Given over
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 15, 2023--
The FDA has approved glofitamab-gxbm (Columvi) for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after two or more lines of systemic therapy.
The drug is a T-cell-engaging bispecific antibody and has been approved for use in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Glofitamab targets CD3, a protein found on the surface of immune T cells in patients with relapsed or refractory diffuse large B-cell lymphoma, and CD20, a healthy or malignant protein that lines the surfaces of B cells.